Uniformly sized liposomes

• US 20080171078A1
• Filed: 01/12/2007
• Published: 07/17/2008
• Est. Priority Date: 01/12/2007
• Status: Abandoned Application

• Current Assignee: Mark Gray
• Original Assignee: Mark Gray
• Inventors: Gray, Mark
• Application Number:
  US11/653,621
• Publication Number:
  US 20080171078A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: B01F 25/3142 the conduit having a plurality of openings in the axial direction or in the circumferential direction
• CPC Class Codes: B01F 25/31424 with a plurality of perforations aligned in a row perpendicular to the flow direction
• CPC Class Codes: B01F 33/30 Micromixers
• CPC Class Codes: B01J 13/04 by physical processes, e.g. drying, spraying

Abstract

Compositions suitable for use as site-specific biological vectors are provided and comprise substantially uniformly sized liposomes having very narrow size distributions. In particular, the compositions comprise a collection of liposomes sufficient in quantity to be administered as a pharmaceutical, wherein the liposomes have a mean outer diameter, D, of from 20 nm to 1000 nm, and at least 95% of the liposomes have an outer diameter of from 0.97 D to 1.03 D. Collections of liposomes with even narrower size distributions are also provided.

Claims

1. A composition for delivering a payload to a patient, comprising a collection of liposomes sufficient in quantity to be administered as a pharmaceutical, wherein the liposomes have a mean outer diameter, D, of from 20 nm to 1000 nm, and at least 95% of the liposomes have an outer diameter of from 0.97 D to 1.03 D.

2. A composition as recited in claim 1, wherein at least 96% of the liposomes have an outer diameter of from 0.97 D to 1.03 D.

3. A composition as recited in claim 1, wherein at least 97% of the liposomes have an outer diameter of from 0.97 D to 1.03 D.

4. A composition as recited in claim 1, wherein at least 98% of the liposomes have an outer diameter of from 0.97 D to 1.03 D.

5. A composition as recited in claim 1, wherein at least 99% of the liposomes have an outer diameter of from 0.97 D to 1.03 D.

11. A composition as recited in claim 1, wherein the collection of liposomes comprises 10⁷ or more liposomes.

17. A composition as recited in claim 1, wherein 25 nm≦

D≦

500 nm.

18. A composition as recited in claim 17, wherein 50 nm≦

D≦

200 nm.

19. A composition as recited in claim 17, wherein 75 nm≦

D≦

125 nm.

20. A composition as recited in claim 17, wherein 90 nm≦

D≦

110 nm.

21. A composition as recited in claim 17, wherein 95 nm≦

D≦

105 nm.

22. A composition as recited in claim 17, wherein D is 100 nm.

23. A composition as recited in claim 1, wherein at least some of the liposomes carry a payload.

24. A composition as recited in claim 23, wherein the payload is carried within the interior of the liposomes.

25. A composition as recited in claim 23, wherein the payload is carried on and/or in the liposomes'"'"' inner and/or outer walls.

26. A composition as recited in claim 23, wherein the payload is selected from the group consisting of amino acids, proteins, enzymes, natural and synthetic nucleic acids, dyes, contrast agents, radiolabeled compounds, fluorescent compounds, medicaments, organic compounds, inorganic compounds, and mixtures thereof.

27. A composition as recited in claim 23, wherein the payload is selected from the group consisting of naturally occurring nucleic acids, synthetic nucleic acids, and mixtures thereof.

28. A composition as recited in claim 23, wherein the payload comprises at least one siRNA.

29. A composition as recited in claim 1, wherein the liposomes are carried in a liquid medium.

30. A composition as recited in claim 29, wherein the liquid is aqueous.

31. A composition as recited in claim 29, further comprising a pH buffer in the medium.

32. A composition as recited in claim 31, wherein the buffer is selected from the group consisting of saline, ammonium sulfate, HEPES, TRIS, and mixtures thereof.

33. A composition as recited in claim 29, further comprising a therapeutic compound carried by the medium.

6. A composition for delivering a payload to a patient, comprising a collection of liposomes sufficient in quantity to be administered as a pharmaceutical, wherein the liposomes have a mean outer diameter, D, of from 20 nm to 1000 nm, and at least 95% of the liposomes have an outer diameter of from 0.98 D to 1.02 D.

7. A composition as recited in claim 6, wherein at least 96% of the liposomes have an outer diameter of from 0.98 D to 1.02 D.

8. A composition as recited in claim 6, wherein at least 97% of the liposomes have an outer diameter of from 0.98 D to 1.02 D.

9. A composition as recited in claim 6, wherein at least 98% of the liposomes have an outer diameter of from 0.98 D to 1.02 D.

10. A composition as recited in claim 6, wherein at least 99% of the liposomes have an outer diameter of from 0.98 D to 1.02 D.

12. A composition for delivering a payload to a patient, comprising

a collection of liposomes sufficient in quantity to be administered as a pharmaceutical, wherein the liposomes have a mean outer diameter, D, of from 20 nm to 1000 nm, and at least 95% of the liposomes have an outer diameter of from 0.99 D to 1.01 D.

13. A composition as recited in claim 12, wherein at least 96% of the liposomes have an outer diameter of from 0.99 D to 1.01 D.

14. A composition as recited in claim 12, wherein at least 97% of the liposomes have an outer diameter of from 0.99 D to 1.01 D.

15. A composition as recited in claim 12, wherein at least 98% of the liposomes have an outer diameter of from 0.99 D to 1.01 D.

16. A composition as recited in claim 12, wherein at least 99% of the liposomes have an outer diameter of from 0.99 D to 1.01 D.

34. A composition for delivering a payload to a patient, comprising a collection of liposomes sufficient in quantity to be administered as a pharmaceutical, wherein the liposomes have a mean outer diameter, D, of from 20 nm to 1000 nm, with a standard deviation ≦

0.015 D.